This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or ...

Please provide your email address to receive an email when new articles are posted on . More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A ...

Common semaglutide side effects include nausea, vomiting, diarrhea, and constipation. These should get better with time. Avoid fatty and greasy foods, and eat smaller meals to minimize ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

Semaglutide led to significant reductions in body weight, blood pressure, cholesterol, and HbA1c, but improvements were smaller than in clinical trials. Patients without diabetes experienced greater ...

Share on Pinterest Semaglutide may be effective in treating a form of fatty liver disease, new research shows. Steve Christo – Corbis/Getty Images Semaglutide is a GLP-1 agonist medication that can ...

Semaglutide could help people drink less alcohol. Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less alcohol. A ...

Please provide your email address to receive an email when new articles are posted on . An update to the FDA drug shortage list on Feb. 21 listed the semaglutide shortage as being resolved. In a press ...

Semaglutide is a prescription medication. Injectable forms of the drug are available under the brand names Ozempic and Wegovy. The pill form of semaglutide is available as the brand-name drug Rybelsus ...

Semaglutide, available under the brand names Ozempic, Wegovy, and the oral tablet Rybelsus, is effective for diabetes and weight management, but like any medication, it may have some side effects.

A woman in her 70s with type 2 diabetes and class 3 obesity with a BMI of 51.1 developed severe oesophagitis after 6 months on weekly semaglutide 0.25 mg. Her gastrointestinal symptoms were initially ...